KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Elevated plasma levels of CXCL16 in severe COVID-19 patients.CytokinePMID 35121493PMC88013182022-Apr0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.Lancet Respir MedPMID 35123660PMC88130652022-Apr0.98未发现恶性肿瘤人群证据。待处理
Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.Gynecol OncolPMID 35177279无 PMCID2022-Apr0.95Study is a Phase III randomized oncology trial with a drug intervention, but lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Primary endpoint is HPV clearance, a binary outcome.待处理
XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).Cancer Commun (Lond)PMID 35212487PMC90177572022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.Eur J CancerPMID 35220182无 PMCID2022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.Lancet OncolPMID 35240053无 PMCID2022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.ESMO OpenPMID 35247871PMC90589042022-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet HaematolPMID 35271808PMC89602852022-Apr0.98未发现恶性肿瘤人群证据。待处理
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.Lung CancerPMID 35278766无 PMCID2022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.Lancet OncolPMID 35279270PMC89602822022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.ESMO OpenPMID 35279527PMC91613942022-Apr0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.Lancet OncolPMID 35298906无 PMCID2022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.EBioMedicinePMID 35306340PMC89338292022-Apr0.75The study is a secondary analysis of circulating tumor DNA and minimal residual disease biomarkers within a phase II/III randomized trial of rectal cancer. While it is oncology, human, randomized, phase-definitive, and reports a time-to-event endpoint (HR for recurrence), it lacks a specified drug-containing intervention (the analysis focuses on biomarker methods, not the trial's therapeutic arms). The report is a secondary biomarker analysis, not the primary trial result.待处理
Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.ESMO OpenPMID 35334418PMC90589052022-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.ESMO OpenPMID 35344750PMC90588662022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.Lancet HaematolPMID 35358441PMC89690572022-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.J Am Soc NephrolPMID 35361724PMC89704502022-Apr0.98未发现恶性肿瘤人群证据。待处理
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.CNS DrugsPMID 35380374PMC89947152022-Apr0.98未发现恶性肿瘤人群证据。待处理
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.J Immunother CancerPMID 35383114PMC89839942022-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.ESMO OpenPMID 35397432PMC90589032022-Apr0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial.Clin TherPMID 35410753无 PMCID2022-Apr0.98未发现恶性肿瘤人群证据。待处理
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.RMD OpenPMID 35428697PMC90140602022-Apr0.95The record is excluded because it is not an oncology study and lacks a time-to-event efficacy endpoint as required.待处理
The Journeying through Dementia psychosocial intervention versus usual care study: a single-blind, parallel group, phase 3 trial.Lancet Healthy LongevPMID 36098301无 PMCID2022-Apr0.98未发现恶性肿瘤人群证据。待处理
Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.Eur Heart JPMID 34405875PMC89709842022-Mar-310.98未发现恶性肿瘤人群证据。待处理
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.J Antimicrob ChemotherPMID 35022730PMC94321342022-Mar-310.98未发现恶性肿瘤人群证据。待处理
Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus.J Antimicrob ChemotherPMID 35045168PMC91260702022-Mar-310.98未发现恶性肿瘤人群证据。待处理
Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes.BMC MedPMID 35346165PMC89620782022-Mar-290.98未发现恶性肿瘤人群证据。待处理
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.Arthritis Res TherPMID 35351194PMC89662572022-Mar-290.98未发现恶性肿瘤人群证据。待处理
Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.VaccinePMID 35232596无 PMCID2022-Mar-250.98未发现恶性肿瘤人群证据。待处理
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.N Engl J MedPMID 35179323PMC98445512022-Mar-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.N Engl J MedPMID 35320642PMC76126782022-Mar-240.98未发现恶性肿瘤人群证据。待处理
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.N Engl J MedPMID 35320644无 PMCID2022-Mar-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).Sci RepPMID 35332216PMC89482512022-Mar-240.98未发现恶性肿瘤人群证据。待处理
A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.J Korean Med SciPMID 35315603PMC89386142022-Mar-210.98未发现恶性肿瘤人群证据。待处理
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.J Clin OncolPMID 35007153PMC89370152022-Mar-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Durability of three types of dual active ingredient long-lasting insecticidal net compared to a pyrethroid-only LLIN in Tanzania: methodology for a prospective cohort study nested in a cluster randomized controlled trial.Malar JPMID 35305667PMC89344982022-Mar-190.98未发现恶性肿瘤人群证据。待处理
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.N Engl J MedPMID 35294811无 PMCID2022-Mar-170.98未发现恶性肿瘤人群证据。待处理
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.Int J Radiat Oncol Biol PhysPMID 34808255无 PMCID2022-Mar-150.85The study is a Phase III randomized trial in oncology with a drug intervention, but the primary endpoint is change in patient-reported oral mucositis symptom scores over time, not a time-to-event efficacy endpoint. Secondary endpoints also focus on quality of life, opioid use, and safety. No time-to-event outcome (e.g., OS, PFS, DFS) or associated analysis (Kaplan-Meier, HR) is reported.待处理
Efficacy and Safety of TJP-008 Compared to 2 L PEG with Ascorbate in Colon Cleansing: A Randomized Phase 3 Trial.Gut LiverPMID 34810296PMC89248132022-Mar-150.98未发现恶性肿瘤人群证据。待处理
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.Am J Respir Crit Care MedPMID 34851799无 PMCID2022-Mar-150.98未发现恶性肿瘤人群证据。待处理
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.Antimicrob Agents ChemotherPMID 34978890PMC89231832022-Mar-150.98未发现恶性肿瘤人群证据。待处理
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.Acta Derm VenereolPMID 35170742PMC95746912022-Mar-150.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.Antimicrob Agents ChemotherPMID 35191746PMC89231682022-Mar-150.98未发现恶性肿瘤人群证据。待处理
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.Cancer CellPMID 35245446无 PMCID2022-Mar-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.BMC Infect DisPMID 35279081PMC89182932022-Mar-120.98未发现恶性肿瘤人群证据。待处理
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.J Clin OncolPMID 34928708PMC89064512022-Mar-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.N Engl J MedPMID 35263518无 PMCID2022-Mar-100.95The record reports a Phase 3 randomized trial in oncology with a drug-containing intervention (radioiodine). However, the primary endpoint is the proportion of patients without events at a fixed time (3 years), not a time-to-event analysis (Kaplan-Meier, HR, TTP, etc.) as required by the adjudication criteria. Therefore, it is ineligible.待处理
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.N Engl J MedPMID 35263519无 PMCID2022-Mar-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.Rev Cardiovasc MedPMID 35345262无 PMCID2022-Mar-100.98未发现恶性肿瘤人群证据。待处理
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.J Natl Cancer InstPMID 34850043PMC89024412022-Mar-080.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理